TNF blocker to protect lungs after transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Lungs & breathing clinical trials.
This early-stage trial tests whether blocking a specific inflammation signal (TNF-alpha) can help prevent or improve kidney problems and early graft (new lung) dysfunction after a lung transplant at Northwestern. You might be eligible if you’re scheduled for that transplant and are willing to go through study consent and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are planning to have a lung transplant at Northwestern Memorial Hospital.
- You can read, understand, and sign the study consent form.
- You have not taken TNF-alpha antibody treatment before and are not taking it now.
- You do not have a positive compatibility blood test (crossmatch) and are not considered highly sensitized (pRA greater than 30%).
- Your transplant team believes study participation is safe for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a long-acting form of tacrolimus (a common anti-rejection medicine) soon after lung transplant. It aims to see if it can be used safely and effectively for people receiving lung transplants at Vanderbilt (VUMC).
This study looks at ways to improve outcomes for people who are waiting for or have recently received a lung transplant. It aims to find better management strategies for both donors and recipients.
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
This trial tests whether blocking a protein called IL-1 with a single dose of anakinra can reduce swelling in the donor lung during the transplant process. If you are having a lung transplant and your donor lung is treated with a machine that keeps it alive outside the body (EVLP), you may be able to join.
This trial tests whether a medication called tranexamic acid (TXA) can help prevent bleeding after a lung transplant biopsy. It compares TXA to a saltwater solution (saline) to see if it reduces the need for procedures to stop bleeding.
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
Hear when a new Lung Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.